Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in...

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Reversible epidermal growth factor receptor (EGFR) inhibitors are effective in non-small cell lung cancer (NSCLC) with activating EGFR mutations.
• Resistance, particularly the T790M mutation, limits the long-term efficacy of current EGFR inhibitors.
• Novel therapeutic strategies are needed to overcome acquired resistance to EGFR-targeted therapies.

Purpose of the Study:

• To develop novel covalent and mutant-selective EGFR inhibitors targeting the T790M resistance mutation.
• To explore a new class of pyrazolopyrimidine-based inhibitors distinct from existing aminopyrimidine scaffolds.
• To evaluate the efficacy and selectivity of these inhibitors against resistant EGFR mutations.

Main Methods:

• Structure-guided drug design and synthesis of pyrazolopyrimidine-based compounds.
• Biochemical assays to assess EGFR kinase inhibitory activity.
• Cell-based assays using drug-resistant (H1975) and wild-type EGFR cell lines.
• In vitro ADME/DMPK profiling and in vivo pharmacokinetic studies in mice.

Main Results:

• Developed covalent inhibitors with a novel pyrazolopyrimidine core structure.
• Demonstrated potent inhibition of T790M mutant EGFR kinase activity.
• Achieved significant inhibition of cell growth in T790M-mutant NSCLC cell lines (H1975).
• Showed selectivity, with minimal impact on wild-type EGFR activity and cell lines.
• Promising in vitro ADME/DMPK and in vivo pharmacokinetic profiles for a lead candidate.

Conclusions:

• The novel pyrazolopyrimidine-based covalent inhibitors effectively target the T790M resistance mutation in EGFR.
• These compounds represent a new class of inhibitors offering a potential strategy to overcome resistance in NSCLC.
• Further development of these inhibitors may lead to improved treatment outcomes for patients with resistant NSCLC.